Mdg target 8 e gap analysis
This presentation is the property of its rightful owner.
Sponsored Links
1 / 6

MDG Target 8.E gap analysis PowerPoint PPT Presentation


  • 101 Views
  • Uploaded on
  • Presentation posted in: General

MDG Target 8.E gap analysis. Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008. Target 8.E: In cooperation with pharmaceutical companies, provide access to affordable essential drugs in developing countries.

Download Presentation

MDG Target 8.E gap analysis

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Mdg target 8 e gap analysis

MDG Target 8.E gap analysis

Ms. Alexandra Cameron

Department of Essential Medicines and Pharmaceutical Policies, World Health Organization

27 August 2008


Mdg target 8 e gap analysis

Target 8.E: In cooperation with pharmaceutical companies, provide access to affordable essential drugs in developing countries

Indicator 8.13. Proportion of Population with Access to Affordable, Essential Drugs on a Sustainable Basis


Who indicators for measurement of access to medicines

WHO indicators for measurement of access to medicines

  • Access to essential medicines/technologies as part of the fulfilment of the right to health, recognized in the constitution or national legislation.

  • Existence and year of last update of a published national medicines policy.

  • Existence and year of last update of a published national list of essential medicines.

  • Legal provisions to allow/encourage generic substitution in the private sector.

  • Public and private per capita expenditure on medicines.

  • Percentage of population covered by health insurance.

  • Average availability of 30 selected essential medicines in public and private health facilities

  • Median consumer price ratio of 30 selected essential medicines in public and private health facilities

  • Margin or mark-up (in per cent) between producer and consumer price


Some key findings

Some key findings

Availability of essential medicines

  • Average public sector availability was only 34.9%. Public sector availability of medicines is is consistently lower than in the private sector where average availability was 63.2%.

    Price of essential medicines

  • Lowest-priced generic medicines cost 6.4 times international reference prices(IRPs) in the private sector.

  • In public sectors in which patients pay for medicines, lowest-priced generics cost about 2.5 times more than IRPs.


Availability of artemether lumefantrine 20 120 mg in kenya

Availability of Artemether/lumefantrine 20/120 mg in Kenya


Mdg target 8 e as an entry point for chronic diseases

MDG Target 8.E as an entry point for chronic diseases

"The Global Fund to Fight AIDS, Tuberculosis and Malaria, The United States President's Emergency Plan for AIDS Relief (PEPFAR), and UNITAID have generated substantial funding for the treatment of HIV/AIDS, Tuberculosis and Malaria. Further support is needed for chronic, noncommunicable diseases such as cardiovascular disease, cancer, diabetes and chronic respiratory disease. Globally, approximately 35 million deaths (60% of all deaths) are attributable to chronic diseases each year, 80% of which occur in low- and middle-income countries."


  • Login